Not Signed In - InterMune Discontinues Phase 3 INSPIRE Trial Of Actimmune In Idiopathic Pulmonary Fibrosis
Tue, 06 Mar 2007 08:00 AM EST
... InterMune, Inc. (Nasdaq: ITMN) today announced that it has discontinued the Phase 3 INSPIRE clinical trial evaluating Actimmune(R) (interferon gamma-1b) in patients with idiopathic pulmonary fibrosis (IPF) based upon the recommendation of the study's independent data monitoring committee (DMC). [click link for full article] ...
Related Topics
- Pulmonary Fibrosis
- Clinical Trials
- Cystic Fibrosis
- Pulmonary Hypertension
- Pulmonary Embolism
- Interferon Gamma-1b Injection
- Interstitial pulmonary fibrosis
- Edema
- Chronic Obstructive Pulmonary Disease
- Chronic Diseases
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Hantavirus Pulmonary Syndrome
- Thrombocytopenia
- Fibrosis
- Cardiomyopathy
- Hives
- COPD (Chronic Obstructive Pulmonary Disease)
- Idiopathic Thrombocytopenia Purpura
- Familial Idiopathic Basal Ganglia Calcification
email this page
print this page
bookmark this page
feedback on this page
